Influence of reduced susceptibility to glycopeptides on activities of vancomycin and teicoplanin against Staphylococcus aureus in experimental endocarditis

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 6, 2003, Pages 2018-2021

  Pavie, Juliette ^a   Lefort, Agnès ^a   Ploy, Marie Cécile ^c   Massias, Laurent ^b   Chau, Françoise ^a   Garry, Louis ^a   Denis, François ^c   Fantin, Bruno ^a,d  

^a INSERM   (France)

^b BICHAT HOSPITAL   (France)

^c LIMOGES UNIVERSITY HOSPITAL   (France)

^d BEAUJON HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPEPTIDE; TEICOPLANIN; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL ENDOCARDITIS; BACTERIAL STRAIN; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MEGADOSE; FEMALE; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; RABBIT; STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTI-BACTERIAL AGENTS; DISEASE MODELS, ANIMAL; ENDOCARDITIS, BACTERIAL; FEMALE; HUMANS; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; RABBITS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TEICOPLANIN; VANCOMYCIN;

EID: 0038440772     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.6.2018-2021.2003     Document Type: Article

References (17)

1. Aeschlimann, J. R., G. P. Allen, E. Hershberger, and M. J. Ryback. 2000. Activities of LY333328 and vancomycin administered alone or in combination with gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model. Antimicrob. Agents Chemother. 44:2991-2998.
2. Aeschlimann, J. R., E. Hershberger, and M. J. Ryback. 1999. Analysis of vancomycin population susceptibility profiles, killing activity, and postantibiotic effect against vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 43:1914-1918.
3. Backo, M., E. Gaenger, A. Burkart, Y. L. Chai, and A. S. Bayer. 1999. Treatment of experimental staphylococcal endocarditis due to a strain with reduced susceptibility to vancomycin: efficacy of ampicillin-sulbactam. Antimicrob. Agents Chemother. 43:2565-2568.
4. Boyle-Vavra, S., S. Berke, J. C. Lee, and R. S. Daum. 2000. Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates. Antimicrob. Agents Chemother. 44:272-277.
5. Centers for Disease Control and Prevention. 1997. Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997. Morb. Mortal. Wkly. Rep. 46:765-766.
6. Climo, M. W., R. L. Patron, and G. L. Archer. 1999. Combinations of vancomycin and beta-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin. Antimicrob. Agents Chemother. 43:1747-1753.
7. Comité de l'Antibiogramme de la Société Française de Microbiologie. 1998. Communiqué. Pathol. Biol. 46:1-16.
8. Crémieux, A. C., B. Mazière, J.M. Vallois, M. Ottaviani, A. Azancot, H. Raffoul, A. Bouvet, J. J. Pocidalo, and C. Carbon. 1988. Evaluation of antibiotic duffusion into cardiac vegetations by quantitative autoradiography. J. Infect. Dis. 159:938-944.
9. Diekema, D. J., M. A. Pfaller, F. J. Schmitz, J. Smayevsky, J. Bell, R. N. Jones, and M. Beach. 2001. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in United States, Canada, Latin America, Europe, and the Western Pacific region for the Sentry antimicrobial surveillance programme, 1997-1999. Clin. Infect. Dis. 32(Suppl. 2):S114-S132.
10. Fantin, B., R. Leclercq, M. Arthur, J. Duval, and C. Carbon. 1991. Influence of low-level resistance to vancomycin on efficacy of teicoplanin and vancomycin for treatment of experimental endocarditis due to Enterococcus faecium. Antimicrob. Agents Chemother. 35:1570-1575.
11. Fridkin, S. K. 2001. Vancomycin-intermediate and -resistant Staphylococcus aureus. What the infectious disease specialist needs to know. Clin. Infect. Dis. 32:108-115.
12. Gilbert, D. N., C. A. Wood, R.C. Kimbrough, and the Infectious Diseases Consortium of Oregon. 1991. Failure of treatment with teicoplanin at 6 milligrams/kilogram/day in patients with Staphylococcus aureus intravascular infection. Antimicrob. Agents Chemother. 35:79-87.
13. Hiramatsu, K., H. Hanaki, T. Ino, K. Yabuta, T. Oguri, and F. C. Tenover. 1997. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40:135-136.
14. Kaatz, G. W., S. M. Seo, N. J. Dorman, and S. A. Lerner. 1990. Emergence of teicoplanin resistance during therapy of Staphylococcus aureus endocarditis. J. Infect. Dis. 162:103-108.
15. National Committee for Clinical Laboratory Standards. 2001. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 5th ed. Approved standard M7-A5. National Committee for Clinical Laboratory Standards, Wayne, Pa.
16. Pearson, R., R. T. Steigbigel, H. T. Davis, and S. W. Chapman. 1980. Method for reliable determination of minimal lethal antibiotic concentrations. Antimicrob. Agents Chemother. 18:699-708.
17. Ploy, M. C., C. Grelaud, C. Martin, L. de Lumley, and F. Denis. 1998. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet 351:1212.